Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07158437
PHASE1
Phase 1 Study of SL-325 in Healthy Volunteers
Sponsor: Shattuck Labs, Inc.
View on ClinicalTrials.gov
Summary
This first-in-human study is a randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose study of SL-325 in healthy volunteers.
Official title: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Phase 1 Study of SL-325 in Healthy Volunteers
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2025-09
Completion Date
2026-07
Last Updated
2025-09-05
Healthy Volunteers
Yes
Conditions
Interventions
BIOLOGICAL
SL-325
DR3 blocking antibody
OTHER
Placebo (Normal Saline)
Normal saline
Locations (1)
Celerion
Lincoln, Nebraska, United States